62 related articles for article (PubMed ID: 10904987)
1. New strategy to treat glomerular inflammation by inhibition of mesangial cell matrix metalloproteinases.
Marti HP
Schweiz Med Wochenschr; 2000 May; 130(21):784-8. PubMed ID: 10904987
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells.
Daniel C; Duffield J; Brunner T; Steinmann-Niggli K; Lods N; Marti HP
J Pharmacol Exp Ther; 2001 Apr; 297(1):57-68. PubMed ID: 11259528
[TBL] [Abstract][Full Text] [Related]
3. The role of matrix metalloproteinases in the activation of mesangial cells.
Marti HP
Transpl Immunol; 2002 May; 9(2-4):97-100. PubMed ID: 12180853
[TBL] [Abstract][Full Text] [Related]
4. Dissociated glucocorticoids equipotently inhibit cytokine- and cAMP-induced matrix degrading proteases in rat mesangial cells.
Eberhardt W; Kilz T; Akool el-S; Müller R; Pfeilschifter J
Biochem Pharmacol; 2005 Aug; 70(3):433-45. PubMed ID: 15963473
[TBL] [Abstract][Full Text] [Related]
5. Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion.
Tomita M; Koike H; Han GD; Shimizu F; Kawachi H
Clin Exp Nephrol; 2004 Mar; 8(1):17-26. PubMed ID: 15067512
[TBL] [Abstract][Full Text] [Related]
6. Role of matrix metalloproteinases in mesangial proliferative glomerulonephritis.
Marti HP
Kidney Blood Press Res; 2000; 23(3-5):199-201. PubMed ID: 11031721
[No Abstract] [Full Text] [Related]
7. Functional role of matrix metalloproteinases (MMPs) in mammary epithelial cell development.
Lee PP; Hwang JJ; Mead L; Ip MM
J Cell Physiol; 2001 Jul; 188(1):75-88. PubMed ID: 11382924
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis and extracellular matrix-cell interactions in kidney disease.
Makino H; Sugiyama H; Kashihara N
Kidney Int Suppl; 2000 Sep; 77():S67-75. PubMed ID: 10997693
[TBL] [Abstract][Full Text] [Related]
9. Rat mesangial cells and matrix metalloproteinase inhibitor: inhibition of 72-kD type IV collagenase (MMP-2) and of cell proliferation.
Steinmann-Niggli K; Lukes M; Marti HP
J Am Soc Nephrol; 1997 Mar; 8(3):395-405. PubMed ID: 9071708
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis.
Steinmann-Niggli K; Ziswiler R; Küng M; Marti HP
J Am Soc Nephrol; 1998 Mar; 9(3):397-407. PubMed ID: 9513901
[TBL] [Abstract][Full Text] [Related]
11. Regulatory mechanism in glomerular mesangial cell proliferation.
Haas CS; Schöcklmann HO; Lang S; Kralewski M; Sterzel RB
J Nephrol; 1999; 12(6):405-15. PubMed ID: 10626832
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML
Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo.
Ahn JD; Morishita R; Kaneda Y; Kim HJ; Kim YD; Lee HJ; Lee KU; Park JY; Kim YH; Park KK; Chang YC; Yoon KH; Kwon HS; Park KG; Lee IK
Gene Ther; 2004 Jun; 11(11):916-23. PubMed ID: 14961072
[TBL] [Abstract][Full Text] [Related]
14. Role of matrix metalloproteinases in the inflammatory response in human airway cell-based assays and in rodent models of airway disease.
Birrell MA; Wong S; Dekkak A; De Alba J; Haj-Yahia S; Belvisi MG
J Pharmacol Exp Ther; 2006 Aug; 318(2):741-50. PubMed ID: 16690722
[TBL] [Abstract][Full Text] [Related]
15. Synthetic matrix metalloproteinase inhibitor decreases early cardiac neural crest migration in chicken embryos.
Cai DH; Brauer PR
Dev Dyn; 2002 Aug; 224(4):441-9. PubMed ID: 12203736
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of mesangial cell proliferation and mesangial matrix expansion by antisense oligodeoxynucleotide targeting preproendothelin-1 mRNA in vivo].
Li M; Chen Y; Zhang Z
Zhonghua Yi Xue Za Zhi; 1999 Feb; 79(2):133-5. PubMed ID: 11601021
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.
Hu J; Van den Steen PE; Sang QX; Opdenakker G
Nat Rev Drug Discov; 2007 Jun; 6(6):480-98. PubMed ID: 17541420
[TBL] [Abstract][Full Text] [Related]
18. [Current aspects in the pathogenesis and therapy of glomerulonephritis: significance of glomerular metalloproteinases].
Marti HP; Lovett DH
Schweiz Med Wochenschr; 1992 Nov; 122(45):1701-7. PubMed ID: 1439688
[TBL] [Abstract][Full Text] [Related]
19. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
20. Human IgA nephritis: immunocytochemical evidence of a chronic inflammatory proliferative disorder.
Yoshioka K; Maki S
Histol Histopathol; 1995 Jan; 10(1):203-12. PubMed ID: 7756738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
